Registrational Dataset from the Phase 1/2 ARROW Trial of Pralsetinib (BLU-667) in Patients with Advanced RET Fusion plus Non-Small-Cell Lung Cancer (NSCLC)

被引：0
|
作者：
Gainor, J. F. [1 ]
Curigliano, G. [2 ]
Kim, D. -W. [3 ]
Lee, D. H. [4 ]
Besse, B. [5 ]
Baik, C. S. [6 ]
Doebele, R. C. [7 ]
Cassier, P. [8 ]
Lopes, G. [9 ]
Tan, D. S. -W. [10 ]
Garralda, E. [11 ]
Paz-Ares, L. [12 ]
Cho, B. C. [13 ]
Gadgeel, S. M. [14 ]
Thomas, M. [15 ]
Liu, S. V. [16 ]
Clifford, C. [17 ]
Zhang, H. [17 ]
Turner, C. D. [17 ]
Subbiah, V. [18 ]
机构：
[1] Massachusetts Gen Hosp, Boston, MA 02114 USA
[2] Univ Milan, European Inst Oncol, IRCCS, Milan, Italy
[3] Seoul Natl Univ Hosp, Seoul, South Korea
[4] Univ Ulsan, Asan Med Ctr, Coll Med, Seoul, South Korea
[5] Gustave Roussy Univ Paris Sud, Villejuif, France
[6] Univ Washington, Sch Med, Main Hosp Seattle, Seattle, WA 98195 USA
[7] Univ Colorado, Canc Ctr, Aurora, CO USA
[8] Ctr Leon Berard, Lyon, France
[9] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA
[10] Natl Canc Ctr Singapore, Singapore, Singapore
[11] Hosp Univ Vall dHebron, Vall dHebron Inst Oncol VHIO, Barcelona, Spain
[12] Hosp Univ 12 Octubre, Madrid, Spain
[13] Yonsei Univ, Yonsei Canc Ctr, Coll Med, Seoul, South Korea
[14] Henry Ford Canc Inst, Detroit, MI USA
[15] Heidelberg Univ Hosp, Thoraxklin, Heidelberg, Germany
[16] Georgetown Univ, Washington, DC USA
[17] Blueprint Med Corp, Cambridge, MA USA
[18] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MO01.38
引用
收藏
页码：S31 / S32
页数：2
相关论文
共 50 条
  • [21] Pralsetinib in patients with RET fusion-positive non-small cell lung cancer: A plain language summary of the ARROW study
    Griesinger, Frank
    Curigliano, Giuseppe
    Subbiah, Vivek
    Baik, Christina S.
    Tan, Daniel S. W.
    Lee, Dae H.
    Misch, Daniel
    Garralda, Elena
    Kim, Dong-Wan
    van der Wekken, Anthonie J.
    Gainor, Justin F.
    Paz-Ares, Luis
    Liu, Stephen, V
    Kalemkerian, Gregory P.
    Bowles, Daniel W.
    Mansfield, Aaron S.
    Lin, Jessica J.
    Smoljanovic, Vlatka
    Rahman, Ahmadur
    Zalutskaya, Alena
    Louie-Gao, Melinda
    Boral, Andy L.
    Mazieres, Julien
    FUTURE ONCOLOGY, 2024, 20 (06) : 297 - 306
  • [22] Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer
    Wang, Lei
    You, Yafei
    He, Wenzhuo
    Hou, Yu
    Li, Lan
    Wang, Li
    Jiang, Chang
    Yi, Jiahong
    Xia, Yaoxiong
    Xia, Liangping
    FRONTIERS IN MEDICINE, 2025, 12
  • [23] A phase II trial of pemetrexed (P) plus carboplatin (C) in patients (pts) with advanced non-small-cell lung cancer (NSCLC).
    Koshy, S
    Herbst, RS
    Obasaju, CK
    Fossella, F
    Papadimitrakopoulou, V
    Pisters, KMW
    Blumenschein, G
    Peeples, BO
    Hong, WK
    Zinner, RG
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 634S - 634S
  • [24] An overview of the role of selpercatinib and pralsetinib in RET-fusion-positive non-small cell lung cancer (NSCLC)
    Nguyen, Vanessa Quang
    Geirnaert, Marc
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023, 29 (02) : 450 - 456
  • [25] Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trial
    Subbiah, Vivek
    Cassier, Philippe A.
    Siena, Salvatore
    Garralda, Elena
    Paz-Ares, Luis
    Garrido, Pilar
    Nadal, Ernest
    Vuky, Jacqueline
    Lopes, Gilberto
    Kalemkerian, Gregory P.
    Bowles, Daniel W.
    Seetharam, Mahesh
    Chang, Jianhua
    Zhang, Hui
    Green, Jennifer
    Zalutskaya, Alena
    Schuler, Martin
    Fan, Yun
    Curigliano, Giuseppe
    NATURE MEDICINE, 2022, 28 (08) : 1640 - +
  • [26] Selpercatinib in Patients With RET Fusion-Positive Non-Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial
    Drilon, Alexander
    Subbiah, Vivek
    Gautschi, Oliver
    Tomasini, Pascale
    de Braud, Filippo
    Solomon, Benjamin J.
    Tan, Daniel Shao-Weng
    Alonso, Guzman
    Wolf, Juergen
    Park, Keunchil
    Goto, Koichi
    Soldatenkova, Victoria
    Szymczak, Sylwia
    Barker, Scott S.
    Puri, Tarun
    Bence Lin, Aimee
    Loong, Herbert
    Besse, Benjamin
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (02) : 385 - +
  • [27] Vinorelbine/gemcitabine in advanced non-small-cell lung cancer (NSCLC): A phase I trial
    Pirker, R
    Krajnik, G
    MohnStaudner, A
    Marhold, F
    Malayeri, R
    Zochbauer, S
    Kummer, F
    Greil, R
    Huber, H
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 1139 - 1139
  • [28] Response to selpercatinib versus prior systemic therapy in patients (pts) with RET fusion plus non-small-cell lung cancer (NSCLC).
    Drilon, Alexander E.
    Gautschi, Oliver
    Besse, Benjamin
    Subbiah, Vivek
    Tan, Daniel Shao-Weng
    Park, Keunchil
    De Braud, Filippo G.
    Alonso, Guzman
    Wolf, Juergen
    Soldatenkova, Victoria
    French, Pearl Plernjit
    Lin, Aimee K.
    Goto, Koichi
    Solomon, Benjamin J.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [29] AcceleRET Lung: A Phase 3 Study of First-Line Pralsetinib in Patients with RET-Fusion plus Advanced/Metastatic NSCLC
    Besse, B.
    Felip, E.
    Kim, E. S.
    Clifford, C.
    Louie-Gao, M.
    Yagui-Beltran, A.
    Popat, S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S44 - S45
  • [30] Alectinib in Previously Treated RET-Rearranged Advanced Non-Small-Cell Lung Cancer: A Phase 1/2 Trial (ALL-RET)
    Yanagitani, N.
    Takeuchi, S.
    Murayama, T.
    Yoshimura, K.
    Imai, Y.
    Takahara, S.
    Kawakami, T.
    Seto, T.
    Hattori, Y.
    Ohashi, K.
    Morise, M.
    Matsumoto, S.
    Yoh, K.
    Goto, K.
    Nishio, M.
    Yano, S.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S207 - S207
12345